C4 Therapeutics shares rise 17.41% intraday after reporting Q4 and full-year 2025 earnings results.

C4 Therapeutics surged 17.41% intraday after reporting earnings results for the fourth quarter and full year ended December 31, 2025, and announcing a corporate presentation. The stock’s sharp rise aligns with investor optimism over its financial performance, though specific earnings details were not disclosed in the summary. Additionally, the company’s scheduled participation in the TD Cowen 46th Annual Healthcare Conference on March 3 may have reinforced market confidence, positioning it as a focal point for investor engagement. The intraday rally suggests strong positive sentiment toward the firm’s recent disclosures and strategic visibility.